Best practices in multiple sclerosis: Infusion reactions versus hypersensitivity associated with biologic therapies
Journal of Infusion Nursing, ISSN: 1533-1458, Vol: 33, Issue: 2, Page: 98-111
2010
- 12Citations
- 40Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes11
- 11
- CrossRef7
- Policy Citations1
- Policy Citation1
- Captures40
- Readers40
- 37
Review Description
Infusion nurses are uniquely positioned to play a vital role in the early identification and management of infusion and hypersensitivity reactions during the administration of biologic therapies. This article reviews the current evidence regarding reactions related to the administration of monoclonal antibodies, namely, natalizumab, a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin, in patients with multiple sclerosis. In addition to differentiating between infusion and hypersensitivity reactions, the article presents general guidelines for the management of these reactions and provides case studies to better illustrate the use of appropriate interventions.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77949544786&origin=inward; http://dx.doi.org/10.1097/nan.0b013e3181cfd36d; http://www.ncbi.nlm.nih.gov/pubmed/20228647; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00129804-201003000-00005; https://journals.lww.com/00129804-201003000-00005; https://dx.doi.org/10.1097/nan.0b013e3181cfd36d; https://journals.lww.com/journalofinfusionnursing/Abstract/2010/03000/Best_Practices_in_Multiple_Sclerosis__Infusion.5.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know